表紙:ジェネリック医薬品の世界市場:業界動向、市場シェア・規模・成長率・機会および予測(2021年~2026年)
市場調査レポート
商品コード
999741

ジェネリック医薬品の世界市場:業界動向、市場シェア・規模・成長率・機会および予測(2021年~2026年)

Generic Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

出版日: | 発行: IMARC Services Private Limited | ページ情報: 英文 116 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.68円
ジェネリック医薬品の世界市場:業界動向、市場シェア・規模・成長率・機会および予測(2021年~2026年)
出版日: 2021年04月12日
発行: IMARC Services Private Limited
ページ情報: 英文 116 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 目次
概要

世界のジェネリック医薬品の市場規模は、2020年に3,860億米ドルに達しました。ジェネリック医薬品は、ブランド薬と同じ有効成分を含み、同等の治療効果を持つ医薬品です。また、安全性、品質、投与量、強度、投与経路、使用目的、効果、形態、品質、および副作用の点でも同じです。これらの薬は、ブランド薬の特許満了後にのみ製造することができます。ブランド薬と比較して、ジェネリック医薬品の製造は、薬の有効性と安全性を実証するために臨床(ヒト)および動物実験を繰り返す必要がないため、はるかに低コストです。研究の初期費用が削減されるため、ジェネリック医薬品は通常、市場で大幅に低い価格で販売されています。

市場動向:

  • 人口の高齢化と慢性疾患の発生率の増加により、先進国の政府はジェネリック医薬品の生産を促進することにより医療費の削減に取り組んできました。一方、新興諸国では、手頃な価格とアクセスしやすさがヘルスケア業界が直面する主要な問題のいくつかです。これらの問題に対処するために、政府やその他の規制機関は、製造業者に効果的なジェネリック医薬品の導入を奨励してきました。しかし、ブランド薬の急速な特許満了にもかかわらず、ジェネリック医薬品は不足しています。この状況は現在、世界中の病院、機関、その他の組織別行われているさまざまなイニシアチブによって修正されています。たとえば、2018年に、米国の7つの病院と3つの慈善団体の連合は、Civica Rxという名前のジェネリック医薬品企業を立ち上げることにより、医薬品の不足と必須医薬品の高コストに対処すると発表しました。同社は、2019年の初めから、市場で入手可能な14の供給不足のFDA承認薬を製造しています。これ以外に、2018年、米国食品医薬品局(USFDA)は、市場参入とジェネリック承認がより効率的になる方針を立て、コピーが難しい医薬品カテゴリーと特定の複雑な医薬品の両方の開発に関するガイダンス文書を発行しました。世界のジェネリック医薬品市場は、今後5年間で安定成長を示すと予想されています。

当レポートは世界のジェネリック医薬品市場について調査しており、業界動向、市場予測、主要国・治療領域・薬物送達・流通チャネル・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 序文

第2章 範囲と調査方法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界のジェネリック医薬品業界

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 国別の市場セグメンテーション
  • 治療領域別の市場セグメンテーション
  • 薬物送達別の市場セグメンテーション
  • 流通チャネル別の市場セグメンテーション
  • SWOT分析
    • 概要
    • 強み
    • 弱点
    • 市場機会
    • 脅威
  • バリューチェーン分析
    • 研究開発
    • 製造
    • マーケティングと流通
  • 一般産業における規制
  • 主要な市場成長要因と成功要因

第6章 主要国市場

  • 米国
  • 中国
  • ブラジル
  • ドイツ
  • フランス
  • インド
  • 英国
  • 日本
  • カナダ
  • イタリア
  • その他

第7章 治療領域別の市場セグメンテーション

  • 中枢神経系
  • 心臓血管
  • 皮膚科
  • 泌尿生殖器/ホルモン
  • 呼吸器
  • リウマチ学
  • 糖尿病
  • 腫瘍学
  • その他

第8章 薬物送達別市場セグメンテーション

  • 経口
  • 注射剤
  • 皮膚/局所
  • 吸入器

第9章 流通チャネル別の市場セグメンテーション

  • 小売薬局
  • 病院薬局

第10章 競合情勢

  • 競争構造
  • 主要企業別市場セグメンテーション
  • 主要企業のプロファイル
    • Teva Pharmaceuticals Industries Ltd.
    • Mylan N.V.
    • Novartis AG
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Fresenius SE & Co.
    • Lupin Limited
    • Endo Pharmaceuticals Inc.
    • Aurobindo Pharma Limited
    • Aspen Pharmacare Holdings Limited

第11章 ジェネリック医薬品の製造プロセス

  • 製品の概要
  • 詳細なプロセスフロー(タブレット)
  • 詳細なプロセスフロー(注射物質)
  • 関係するさまざまな種類の単位操作
  • 物質収支と原材料の要件

第12章 プロジェクトの詳細、要件、および関連するコスト

  • 土地の要件と支出
  • 建設要件と支出
  • 工場の機械
  • 機械のイメージ
  • 原材料の要件と支出
  • 梱包要件と支出
  • 輸送要件と支出
  • ユーティリティの要件と支出
  • マンパワーの要件と支出
  • その他の設備投資

第13章 ローンと財政支援

第14章 プロジェクトの経済学

  • プロジェクトの資本コスト
  • 技術経済パラメータ
  • サプライチェーンのさまざまなレベルにわたる製品の価格設定とマージン
  • 課税と減価償却
  • 収入予測
  • 支出予測
  • 財務分析
  • 利益分析

図一覧

表一覧

目次
Product Code: SR1020B127_Report

The global generic drugs market reached a value of US$ 386 Billion in 2020. A generic drug is a medicine that contains the same active ingredient and has an equivalent therapeutic effect as the branded drug. It is also identical in terms of safety, quality, dosage, strength, route of administration, intended use, effect, form, quality and side effects. These medications can be produced only after the patent expiration of the brand-name drug. As compared to branded drugs, the production of generics costs much less as it does not require the repetition of clinical (human) and animal studies to demonstrate the effectiveness and safety of the medicine. Due to a reduction in the upfront cost of research, generics are typically sold at a substantially lower price in the market.

Market Trends:

  • Due to an aging population and increasing incidences of chronic diseases, governments of developed countries have been making efforts to reduce healthcare costs by promoting the production of generics. Whereas, in developing countries, affordability and accessibility are some of the primary issues faced by the healthcare industry. To address these problems, governments and other regulatory bodies have been encouraging manufacturers to introduce effective generic drugs. However, despite the rapid patent expiry of branded drugs, there has been a shortage of generics. This situation is currently being rectified by various initiatives taken by hospitals, institutions and other organizations across the globe. For instance, in 2018, a coalition of seven hospitals and three philanthropies in the US announced that they would be addressing drug shortages and the high cost of essential medications by launching a generic drug company, named Civica Rx. The company is producing 14 short-supply, FDA-approved drugs that have been available in the market since the beginning of 2019. Other than this, in 2018, the United States Food and Drug Administration (USFDA) created policies to make the process of market entry and generic approval more efficient. It issued guidance documents for the development of both hard-to-copy drug categories and specific complex drugs. Looking forward, IMARC Group expects the global generic drugs market to exhibit moderate growth during the next five years.

Breakup by Therapy Area:

  • Central Nervous System
  • Cardiovascular
  • Dermatology
  • Genitourinary/Hormonal
  • Respiratory
  • Rheumatology
  • Diabetes
  • Oncology
  • Others
  • Cardiovascular diseases (CVDs) are the leading therapy area, accounting for the majority of the total market, on account of the increasing cases of CVDs as a result of unhealthy eating habits and sedentary lifestyles.

Breakup by Drug Delivery:

  • Oral
  • Injectables
  • Dermal/Topical
  • Inhalers
  • Currently, oral medicines are the most preferred product, owing to the convenience attached to their administration, which requires minimal to no medical assistance.

Breakup by Distribution Channel:

  • Retail Pharmacies
  • Hospital Pharmacies
  • At present, the majority of the generics are distributed through retail pharmacy stores as most generic drugs are over the counter (OTC) medicines that can be bought without a prescription.

Regional Insights:

  • United States
  • China
  • Brazil
  • Germany
  • France
  • India
  • United Kingdom
  • Japan
  • Canada
  • Italy
  • Others
  • On a regional basis, the United States represents the biggest market, accounting for the largest market share. This growth is led by numerous initiatives by the US Government to improve generic drug manufacturing and access in the country.

Competitive Landscape:

  • The market is fragmented in nature with the presence of various small and large manufacturers. Some of the leading players operating in the market include Teva Pharmaceuticals Industries Ltd., Mylan N.V., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Fresenius SE & Co., Lupin Limited, Endo Pharmaceuticals Inc., Aurobindo Pharma Limited, and Aspen Pharmacare Holdings Limited.

Key Questions Answered in This Report:

  • How has the market performed so far and how will it perform in the coming years?
  • What are the key regional markets?
  • What has been the impact of COVID-19 on the global generic drugs market?
  • What are the major drug delivery segments?
  • What are the key therapy areas?
  • What are the major distribution channels?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the industry and who are the key players?
  • What is the degree of competition in the industry?
  • What are the profit margins in the industry?
  • What are the key requirements for setting up a manufacturing plant?
  • How are generic drugs manufactured?
  • What are the various unit operations involved in a manufacturing plant?
  • What is the total size of land required for setting up a manufacturing plant?
  • What are the machinery requirements for setting up a manufacturing plant?
  • What are the raw material requirements for setting up a manufacturing plant?
  • What are the packaging requirements for generic drugs?
  • What are the transportation requirements for generic drugs?
  • What are the utility requirements for setting up a manufacturing plant?
  • What are the manpower requirements for setting up a manufacturing plant?
  • What are the infrastructure costs for setting up a manufacturing plant?
  • What are the capital costs for setting up a manufacturing plant?
  • What are the operating costs for setting up a manufacturing plant?
  • What will be the income and expenditures for a manufacturing plant?
  • What is the time required to break-even?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Generic Drugs Industry

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Country
  • 5.5 Market Breakup by Therapy Area
  • 5.6 Market Breakup by Drug Delivery
  • 5.7 Market Breakup by Distribution Channel
  • 5.8 Market Forecast
  • 5.9 SWOT Analysis
    • 5.9.1 Overview
    • 5.9.2 Strengths
    • 5.9.3 Weaknesses
    • 5.9.4 Opportunities
    • 5.9.5 Threats
  • 5.10 Value Chain Analysis
    • 5.10.1 Research and Development
    • 5.10.2 Manufacturing
    • 5.10.3 Marketing and Distribution
  • 5.11 Porter's Five Forces Analysis
    • 5.11.1 Overview
    • 5.11.2 Bargaining Power of Buyers
    • 5.11.3 Bargaining Power of Suppliers
    • 5.11.4 Degree of Competition
    • 5.11.5 Threat of New Entrants
    • 5.11.6 Threat of Substitutes
  • 5.12 Regulations in the Generic Industry
  • 5.13 Key Market Drivers and Success Factors

6 Performance of Key Countries

  • 6.1 United States
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 China
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Brazil
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Germany
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 France
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 India
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 United Kingdom
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast
  • 6.8 Japan
    • 6.8.1 Market Trends
    • 6.8.2 Market Forecast
  • 6.9 Canada
    • 6.9.1 Market Trends
    • 6.9.2 Market Forecast
  • 6.10 Italy
    • 6.10.1 Market Trends
    • 6.10.2 Market Forecast
  • 6.11 Others
    • 6.11.1 Market Trends
    • 6.11.2 Market Forecast

7 Market Breakup by Therapy Area

  • 7.1 Central Nervous System
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cardiovascular
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Dermatology
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Genitourinary/Hormonal
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Respiratory
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Rheumatology
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Diabetes
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast
  • 7.8 Oncology
    • 7.8.1 Market Trends
    • 7.8.2 Market Forecast
  • 7.9 Others
    • 7.9.1 Market Trends
    • 7.9.2 Market Forecast

8 Market Breakup by Drug Delivery

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Injectables
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Dermal/Topical
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Inhalers
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Retail Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Hospital Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Competitive Landscape

  • 10.1 Competitive Structure
  • 10.2 Market Breakup by Key Players
  • 10.3 Key Player Profiles
    • 10.3.1 Teva Pharmaceuticals Industries Ltd.
    • 10.3.2 Mylan N.V.
    • 10.3.3 Novartis AG
    • 10.3.4 Pfizer Inc.
    • 10.3.5 Sun Pharmaceutical Industries Ltd.
    • 10.3.6 Fresenius SE & Co.
    • 10.3.7 Lupin Limited
    • 10.3.8 Endo Pharmaceuticals Inc.
    • 10.3.9 Aurobindo Pharma Limited
    • 10.3.10 Aspen Pharmacare Holdings Limited

11 Generic Drugs Manufacturing Process

  • 11.1 Product Overview
  • 11.2 Detailed Process Flow (Tablets)
  • 11.3 Detailed Process Flow (Injectable)
  • 11.4 Various Types of Unit Operations Involved
  • 11.5 Mass Balance and Raw Material Requirements

12 Project Details, Requirements and Costs Involved

  • 12.1 Land Requirements and Expenditures
  • 12.2 Construction Requirements and Expenditures
  • 12.3 Plant Machinery
  • 12.4 Machinery Pictures
  • 12.5 Raw Material Requirements and Expenditures
  • 12.6 Packaging Requirements and Expenditures
  • 12.7 Transportation Requirements and Expenditures
  • 12.8 Utility Requirements and Expenditures
  • 12.9 Manpower Requirements and Expenditures
  • 12.10 Other Capital Investments

13 Loans and Financial Assistance

14 Project Economics

  • 14.1 Capital Cost of the Project
  • 14.2 Techno-Economic Parameters
  • 14.3 Product Pricing and Margins Across Various Levels of the Supply Chain
  • 14.4 Taxation and Depreciation
  • 14.5 Income Projections
  • 14.6 Expenditure Projections
  • 14.7 Financial Analysis
  • 14.8 Profit Analysis

List of Figure

  • Figure 1: Global: Generic Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Generic Drugs Market: Sales Value Trends (in Billion US$), 2015-2020
  • Figure 3: Global: Generic Drugs Market Forecast: Sales Value Trends (in Billion US$), 2021-2026
  • Figure 4: Global: Generic Drugs Market: Breakup by Country (in %), 2020
  • Figure 5: Global: Generic Drugs Market: Breakup by Therapy Area (in %), 2020
  • Figure 6: Global: Generic Drugs Market: Breakup by Drug Delivery (in %), 2020
  • Figure 7: Global: Generic Drugs Market: Breakup by Distribution Channel (in %), 2020
  • Figure 8: Global: Generic Drugs Industry: SWOT Analysis
  • Figure 9: Global: Generic Drugs Industry: Value Chain Analysis
  • Figure 10: Global: Generic Drugs Industry: Porter's Five Forces Analysis
  • Figure 11: USA: Generic Drugs Market (in Million US$), 2015 & 2020
  • Figure 12: USA: Generic Drugs Market Forecast (in Million US$), 2021-2026
  • Figure 13: China: Generic Drugs Market (in Million US$), 2015 & 2020
  • Figure 14: China: Generic Drugs Market Forecast (in Million US$), 2021-2026
  • Figure 15: Brazil: Generic Drugs Market (in Million US$), 2015 & 2020
  • Figure 16: Brazil: Generic Drugs Market Forecast (in Million US$), 2021-2026
  • Figure 17: Germany: Generic Drugs Market (in Million US$), 2015 & 2020
  • Figure 18: Germany: Generic Drugs Market Forecast (in Million US$), 2021-2026
  • Figure 19: France: Generic Drugs Market (in Million US$), 2015 & 2020
  • Figure 20: France: Generic Drugs Market Forecast (in Million US$), 2021-2026
  • Figure 21: India: Generic Drugs Market (in Million US$), 2015 & 2020
  • Figure 22: India: Generic Drugs Market Forecast (in Million US$), 2021-2026
  • Figure 23: United Kingdom: Generic Drugs Market (in Million US$), 2015 & 2020
  • Figure 24: United Kingdom: Generic Drugs Market Forecast (in Million US$), 2021-2026
  • Figure 25: Japan: Generic Drugs Market (in Million US$), 2015 & 2020
  • Figure 26: Japan: Generic Drugs Market Forecast (in Million US$), 2021-2026
  • Figure 27: Canada: Generic Drugs Market (in Million US$), 2015 & 2020
  • Figure 28: Canada: Generic Drugs Market Forecast (in Million US$), 2021-2026
  • Figure 29: Italy: Generic Drugs Market (in Million US$), 2015 & 2020
  • Figure 30: Italy: Generic Drugs Market Forecast (in Million US$), 2021-2026
  • Figure 31: Global: Generic Drugs Market: Orals (in Million US$), 2015 & 2020
  • Figure 32: Global: Generic Drugs Market Forecast: Orals (in Million US$), 2021-2026
  • Figure 33: Global: Generic Drugs Market: Injectables (in Million US$), 2015 & 2020
  • Figure 34: Global: Generic Drugs Market Forecast: Injectables (in Million US$), 2021-2026
  • Figure 35: Global: Generic Drugs Market: Dermal/Topical (in Million US$), 2015 & 2020
  • Figure 36: Global: Generic Drugs Market Forecast: Dermal/Topical (in Million US$), 2021-2026
  • Figure 37: Global: Generic Drugs Market: Inhalers (in Million US$), 2015 & 2020
  • Figure 38: Global: Generic Drugs Market Forecast: Inhalers (in Million US$), 2021-2026
  • Figure 39: Global: Generic Drugs Market: Central Nervous System (in Million US$), 2015 & 2020
  • Figure 40: Global: Generic Drugs Market Forecast: Central Nervous System (in Million US$), 2021-2026
  • Figure 41: Global: Generic Drugs Market: Cardiovascular (in Million US$), 2015 & 2020
  • Figure 42: Global: Generic Drugs Market Forecast: Cardiovascular (in Million US$), 2021-2026
  • Figure 43: Global: Generic Drugs Market: Dermatology (in Million US$), 2015 & 2020
  • Figure 44: Global: Generic Drugs Market Forecast: Dermatology (in Million US$), 2021-2026
  • Figure 45: Global: Generic Drugs Market: Genitourinary/Hormonal (in Million US$), 2015 & 2020
  • Figure 46: Global: Generic Drugs Market Forecast: Genitourinary/Hormonal (in Million US$), 2021-2026
  • Figure 47: Global: Generic Drugs Market: Respiratory (in Million US$), 2015 & 2020
  • Figure 48: Global: Generic Drugs Market Forecast: Respiratory (in Million US$), 2021-2026
  • Figure 49: Global: Generic Drugs Market: Rheumatology (in Million US$), 2015 & 2020
  • Figure 50: Global: Generic Drugs Market Forecast: Rheumatology (in Million US$), 2021-2026
  • Figure 51: Global: Generic Drugs Market: Diabetes (in Million US$), 2015 & 2020
  • Figure 52: Global: Generic Drugs Market Forecast: Diabetes (in Million US$), 2021-2026
  • Figure 53: Global: Generic Drugs Market: Oncology (in Million US$), 2015 & 2020
  • Figure 54: Global: Generic Drugs Market Forecast: Oncology (in Million US$), 2021-2026
  • Figure 55: Global: Generic Drugs Market: Other Therapy Areas (in Million US$), 2015 & 2020
  • Figure 56: Global: Generic Drugs Market Forecast: Other Therapy Areas (in Million US$), 2021-2026
  • Figure 57: Global: Generic Drugs Market: Retail Pharmacies (in Million US$), 2015 & 2020
  • Figure 58: Global: Generic Drugs Market Forecast: Retail Pharmacies (in Million US$), 2021-2026
  • Figure 59: Global: Generic Drugs Market: Hospital Pharmacies (in Million US$), 2015 & 2020
  • Figure 60: Global: Generic Drugs Market Forecast: Hospital Pharmacies (in Million US$), 2021-2026
  • Figure 61: Generic Drugs Industry: Profit Margins at Various Levels of the Supply Chain
  • Figure 62: Generic Drugs Manufacturing: Production Cost Breakup (in %)
  • Figure 63: Generic Drugs Manufacturing: Detailed Process Flow
  • Figure 64: Generic Drugs Manufacturing Process: Conversion Rate of Feedstocks
  • Figure 65: Generic Drugs Manufacturing: Proposed Plant Layout
  • Figure 66: Generic Drugs Manufacturing Plant: Breakup of Capital Costs (in %)

List of Table

  • Table 1: Global: Generic Drugs Market: Key Industry Highlights, 2020 and 2026
  • Table 2: Global: Generic Drugs Market Forecast: Breakup by Country (in Million US$), 2021-2026
  • Table 3: Global: Generic Drugs Market Forecast: Breakup by Therapy Area (in Million US$), 2021-2026
  • Table 4: Global: Generic Drugs Market Forecast: Breakup by Drug Delivery (in Million US$), 2021-2026
  • Table 5: Global: Generic Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2021-2026
  • Table 6: Generic Drugs Market: Competitive Structure
  • Table 7: Generic Drugs Market: Key Players
  • Table 8: Generic Drugs Manufacturing Plant: Costs Related to Land and Site Development (in US$)
  • Table 9: Generic Drugs Manufacturing Plant: Costs Related to Civil Works (in US$)
  • Table 10: Generic Drugs Manufacturing Plant: Costs Related to Machinery Unit (in US$)
  • Table 11: Generic Drugs Manufacturing Plant: Raw Material Requirements
  • Table 12: Generic Drugs Manufacturing Plant: Costs Related to Salaries and Wages (in US$)
  • Table 13: Generic Drugs Manufacturing Plant: Costs Related to Other Capital Investments (in US$)
  • Table 14: Details of Financial Assistance Offered by Financial Institutions
  • Table 15: Generic Drugs Manufacturing Plant: Capital Costs (in US$)
  • Table 16: Generic Drugs Manufacturing Plant: Techno-Economic Parameters
  • Table 17: Generic Drugs Manufacturing Plant: Taxation and Depreciation (in US$)
  • Table 18: Generic Drugs Manufacturing Plant: Income Projections (in US$)
  • Table 19: Generic Drugs Manufacturing Plant: Expenditure Projections (in US$)
  • Table 20: Generic Drugs Manufacturing Plant: Cash Flow Analysis Without Considering the Income Tax Liability (in US$)
  • Table 21: Generic Drugs Manufacturing Plant: Cash Flow Analysis on Considering the Income Tax Liability (in US$)
  • Table 22: Generic Drugs Manufacturing Plant: Profit and Loss Account (in US$)